Abstract: The present disclosure relates to a pharmaceutical composition or a food composition which has excellent activity of stimulating enteroendocrine cells while being safe with few side effects. The composition contains one or more of an Oldenlandia brachypoda extract, a Spergularia marina extract, a Disporum smilacinum extract, a Persicaria posumbu extract and a Geum aleppicum extract as an active ingredient. The composition of the present disclosure can be usefully used as a pharmaceutical composition or a food composition for preventing, improving or treating diabetes mellitus, improving or treating heart diseases, improving or treating arteriosclerosis, improving or treating digestive disorders and malabsorption, preventing or treating obesity or suppressing appetite, protecting nerves, treating or improving liver diseases, and so forth.

Abstract: A composition for enhancing sweetness includes glycan or glycopeptide derived from soy sauce. The composition has excellent sweetness enhancing properties, and particularly has a sweetening effect nearly the same as or better than those of conventional sweeteners and less calories in terms of nutritional characteristics. A sweetener composition includes the composition for enhancing sweetness and a sweetener. A food includes the composition for enhancing sweetness. A method for enhancing sweetness of a food, includes applying the sweetness enhancer composition to the food. The sweetness enhancer of the present invention is a natural product-derived substance, and contains, as an active ingredient, peptide separated from Korean traditional soy sauce aged over a long period of time, and therefore, may solve problems of conventional chemosynthesized sweetness enhancers, for example, side effects, foul taste or the like.

Abstract: A coniferyl alcohol or a Compositae family, Brassicaceae family, Umbelliferae family, Lamiaceae family, Liliaceae family or Amaranthaceae plant extract provides various uses associated with hTRPA1 activation, and, being a natural compound, involves relatively few side effects in the body and has substantial industrial applicability. The coniferyl alcohol or the Compositae family, Brassicaceae family, Umbelliferae family, Lamiaceae family, Liliaceae family or Amaranthaceae plant extract of the present invention not only will be a novel medical or food raw material which is helpful in maintaining homeostasis in the body associated with hTRPA1 activation, but can also be used to advantage in hTRPA1 antagonist screening.

Abstract: The present disclosure relates to a pharmaceutical composition or a food composition which has excellent activity of stimulating enteroendocrine cells while being safe with few side effects. The composition contains one or more of an Oldenlandia brachypoda extract, a Spergularia marina extract, a Disporum smilacinum extract, a Persicaria posumbu extract and a Geum aleppicum extract as an active ingredient. The composition of the present disclosure can be usefully used as a pharmaceutical composition or a food composition for preventing, improving or treating diabetes mellitus, improving or treating heart diseases, improving or treating arteriosclerosis, improving or treating digestive disorders and malabsorption, preventing or treating obesity or suppressing appetite, protecting nerves, treating or improving liver diseases, and so forth.

Abstract: A coniferyl alcohol or a Compositae family, Brassicaceae family, Umbelliferae family, Lamiaceae family, Liliaceae family or Amaranthaceae plant extract provides various uses associated with hTRPA1 activation, and, being a natural compound, involves relatively few side effects in the body and has substantial industrial applicability. The coniferyl alcohol or the Compositae family, Brassicaceae family, Umbelliferae family, Lamiaceae family, Liliaceae family or Amaranthaceae plant extract of the present invention not only will be a novel medical or food raw material which is helpful in maintaining homeostasis in the body associated with hTRPA1 activation, but can also be used to advantage in hTRPA1 antagonist screening.

Abstract: A composition for enhancing sweetness includes glycan or glycopeptide derived from soy sauce. The composition has excellent sweetness enhancing properties, and particularly has a sweetening effect nearly the same as or better than those of conventional sweeteners and less calories in terms of nutritional characteristics. A sweetener composition includes the composition for enhancing sweetness and a sweetener. A food includes the composition for enhancing sweetness. A method for enhancing sweetness of a food, includes applying the sweetness enhancer composition to the food. The sweetness enhancer of the present invention is a natural product-derived substance, and contains, as an active ingredient, peptide separated from Korean traditional soy sauce aged over a long period of time, and therefore, may solve problems of conventional chemosynthesized sweetness enhancers, for example, side effects, foul taste or the like.

Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide according to the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and thus functions as a TRPV1 activity modulator. Therefore, the present Maillard peptide can be used as a pharmaceutical composition for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic/allergic/inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.